Aging muscle weakness traced to nerve-muscle failure — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- W. David Arnold and University of Missouri-Columbia researchers found the neuromuscular junction — the point where nerves communicate with muscles — becomes less reliable with age, contributing to sarcopenia, a condition affecting nearly half of adults over 80.
- The failure is linked to lower levels of the NaV1.4 protein that helps muscle fibers respond to nerve signals, challenging the long-held assumption that the junction remains reliable during aging.
- NMD Pharma, a Danish biotech, developed a therapy that partially inhibits the ClC-1 protein; in animal models, this improved aging muscles' responsiveness to nerve signals and increased muscle strength.
- Arnold previously served as an investigator in a multicenter clinical trial of ignaseclant — NMD Pharma's ClC-1 inhibitor — for Charcot-Marie-Tooth disease, with topline improvements in muscle strength and physical function presented at the 2026 MDA Clinical & Scientific Conference.
- The study, published in The Journal of Clinical Investigation, brought together collaborators from Denmark, Scotland, Saudi Arabia, and India, with neuromuscular junction expert Hiroshi Nishimune joining the team from Tokyo to provide specialized imaging expertise.
Why it matters: By pinning sarcopenia to NaV1.4 loss and showing ClC-1 inhibition reverses muscle weakness in animals, the Missouri team gives NMD Pharma a mechanistic path to repurpose ignaseclant — already in human trials for Charcot-Marie-Tooth — for the roughly 50% of adults over 80 who lose strength to sarcopenia and currently have no targeted treatment.
Ask SkimNews
